

**EXPERTISE AND SERVICE PROVISION
QUALITY OF LABORATORIES**

**EXTERNAL QUALITY ASSESSMENT
IN VETERINARY MEDICINE**

Definitive GLOBAL REPORT

**Veterinary Medicine
Q-Fever
SURVEY 2021/12**

Sciensano/PT VET/Q-Fever/1-E

Expertise and service provision
Quality of laboratories
J. Wytsmanstreet, 14
1050 Brussels | Belgium

www.sciensano.be

COMMITTEE OF EXPERTS

Sciensano					
Secretariat		PHONE:	02/642.55.22	FAX:	02/642.56.45
Name scheme coordinator	Bernard China	PHONE:	02/652.53.85		
		e-mail:	Bernard.China@sciensano.be		
Name scheme coordinator in training	Ynse Van de Maele	PHONE:	02/642 55 24		
		e-mail:	Ynse.VandeMaele@sciensano.be		
Name alternate scheme coordinator	Arnaud Capron	PHONE:	02/642 53 97		
		e-mail:	Arnaud.Capron@sciensano.be		
Experts	Institute				
Marcella.Mori	Sciensano				

A preliminary version of this report was submitted to the experts on: 06/01/2022

Authorization to release the report: By Bernard China (scheme coordinator) and Ynse Van de Maele (scheme coordinator in training) on 08/02/2022.

All the reports are also available on our webpage:

https://www.wiv-isp.be/QML/activities/external_quality/rapports/ nl/rapports_annee.htm

https://www.wiv-isp.be/QML/activities/external_quality/rapports/ fr/rapports_annee.htm

TABLE OF CONTENTS

INTRODUCTION	4
ORGANS	4
<i>Homogeneity</i>	<i>4</i>
<i>The participants</i>	<i>4</i>
<i>Target Values.....</i>	<i>4</i>
<i>Stability</i>	<i>4</i>
<i>Randomisation and panel composition.....</i>	<i>5</i>
MILK	5
<i>Homogeneity.....</i>	<i>5</i>
<i>The participants</i>	<i>5</i>
<i>Target Values.....</i>	<i>5</i>
<i>Stability</i>	<i>5</i>
<i>Randomisation and panel composition.....</i>	<i>6</i>
SURVEY TIMELINE	6
RESULTS	7
ORGANS	7
<i>Results per sample</i>	<i>7</i>
<i>Used method.....</i>	<i>7</i>
<i>Conclusion</i>	<i>7</i>
MILK	8
<i>Results per sample</i>	<i>8</i>
<i>Used method.....</i>	<i>8</i>
<i>Conclusion</i>	<i>8</i>
ANNEXES (NOT UNDER ACCREDITATION)	9
ANNEX 1: QUANTITATIVE RESULTS.....	9
<i>Sample: PT2021QFVBACMP1</i>	<i>9</i>
<i>Sample: PT2021QFVBACMP2</i>	<i>10</i>
ANNEX 2: ADDITIONAL INFORMATION	10
GRAPHICAL REPRESENTATION.....	11

INTRODUCTION

This survey was dedicated to detect the agent of Q-Fever (*Coxiella burnetii*) by RT-qPCR in organ and milk samples.

The samples were prepared by the National Reference Laboratory (NRL), Veterinary Bacteriology, Scientific Directorate infectious diseases in animals, Sciensano.

For each reference sample, a certificate containing the status of the sample (= 'golden standard') was made. The status of the reference samples was based on (i) the historical background of the animals/farm and (ii) the results obtained by analytical tests (pre-verification before sending). The pre-verification tests consisted of an *in-house* extraction protocols, SOP/PRE/03, and a subsequent RT-qPCR assay using again an *in-house* method (SOP/BAC/ANA15).

Organs were obtained by spiking inactivated animal material free of *C.burnetii*. Samples were spiked with serial dilutions (10^{-1} , 10^{-2} , 10^{-3}) of confluent inactivated cell cultures infected with an avirulent (phase II) *C.burnetii* strain (RSA 439). The estimated concentrations of *C.burnetii* bacteria in the spiked samples were of $1.03E+05$, $1.03E+04$ and $1.03E+03$ genomic equivalent (GE)/ml, respectively.

The reference milk samples were obtained from bulk tank milks of sheep/goat/cattle farms naturally infected or free of *C.burnetii*. All milks were inactivated (internal procedure) and lyophilized before sending.

Organs

Homogeneity

The homogeneity of the samples was tested by the NRL before the survey. The samples were considered homogeneous.

The participants

Six laboratories participated to the Bacteriology survey: Sciensano, ARSIA, LNCR/ACSEDIATE, IDVET, Anses-SOPHIA ANTIPOLIS and LSI-Thermofisher Scientific.

Target Values

The target values were determined by the NRL based on the homogeneity tests.

- PT2021QFVBACOP1, PT2021QFVBACOP2 and PT2021QFVBACOP3 are considered positive.
- PT2021QFVBACON1 and PT2021QFVBACON2 are considered negative.

Stability

The samples were tested before and after the survey. The results were compared and the samples were considered as stable.

Randomisation and panel composition

Since a specific number has been assigned to each laboratory, the randomisation has been performed as follows:

Sample ID	97504	97507	97510
QFO21-1	PT2021QFVBACOP3	PT2021QFVBACOP1	PT2021QFVBACON2
QFO21-2	PT2021QFVBACON2	PT2021QFVBACON1	PT2021QFVBACOP2
QFO21-3	PT2021QFVBACOP1	PT2021QFVBACOP2	PT2021QFVBACON1
QFO21-4	PT2021QFVBACOP2	PT2021QFVBACOP3	PT2021QFVBACOP3
QFO21-5	PT2021QFVBACON1	PT2021QFVBACON2	PT2021QFVBACOP1
Sample ID	97522	97523	97534
QFO21-1	PT2021QFVBACOP3	PT2021QFVBACOP3	PT2021QFVBACOP2
QFO21-2	PT2021QFVBACOP1	PT2021QFVBACON2	PT2021QFVBACON1
QFO21-3	PT2021QFVBACON1	PT2021QFVBACON1	PT2021QFVBACON2
QFO21-4	PT2021QFVBACON2	PT2021QFVBACOP1	PT2021QFVBACOP1
QFO21-5	PT2021QFVBACOP2	PT2021QFVBACOP2	PT2021QFVBACOP3

The panel consisted of 5 different samples.

Milk

Homogeneity

The homogeneity of the samples was tested by the NRL before the survey. The samples were considered homogeneous.

The participants

Six laboratories participated to the Bacteriology survey: Sciensano, ARSIA, LNCR/ACSEDIATE, IDVET, Anses-SOPHIA ANTIPOLIS and LSI-Thermofisher Scientific.

Target Values

The target values were determined by the NRL based on the homogeneity tests.

- PT2021QFVBACMP1 and PT2021QFVBACMP2 are considered positive.
- PT2021QFVBACMN1 is considered negative.

Stability

The samples were tested before and after the survey. The results were compared and the samples were considered as stable.

Randomisation and panel composition

Since a specific number has been assigned to each laboratory, the randomisation has been performed as follows:

Sample ID	97504	97507	97510
QFM21-1	PT2021QFVBACMP2	PT2021QFVBACMP2	PT2021QFVBACMP2
QFM21-2	PT2021QFVBACMP1	PT2021QFVBACMP1	PT2021QFVBACMP2
QFM21-3	PT2021QFVBACMN1	PT2021QFVBACMP2	PT2021QFVBACMN1
QFM21-4	PT2021QFVBACMP1	PT2021QFVBACMP1	PT2021QFVBACMP1
QFM21-5	PT2021QFVBACMP2	PT2021QFVBACMN1	PT2021QFVBACMP1
Sample ID	97522	97523	97534
QFM21-1	PT2021QFVBACMP2	PT2021QFVBACMN1	PT2021QFVBACMP2
QFM21-2	PT2021QFVBACMP2	PT2021QFVBACMP2	PT2021QFVBACMP1
QFM21-3	PT2021QFVBACMP1	PT2021QFVBACMP1	PT2021QFVBACMP2
QFM21-4	PT2021QFVBACMP1	PT2021QFVBACMP2	PT2021QFVBACMN1
QFM21-5	PT2021QFVBACMN1	PT2021QFVBACMP1	PT2021QFVBACMP1

The panel consisted of 3 different samples.

Survey timeline

Transfer of the samples from NRL to QL: 12/10/2021

Randomization of the samples by QL: 14/10/2021

Sending samples (sent on dry ice) to participants: 18/10/2021

Deadline for the results encoding: 18/11/2021

Preliminary report: 06/01/2022

RESULTS

Organs

The panel consisted of 5 different samples: 3 positive and 2 negative samples.

Results per sample

Sample ID	Status	Number of repetitions (total results)	Observed result
OP1	POS	1 (6)	6 POS
OP2	POS	1 (6)	5 POS 1 false NEG
OP3	POS	1 (6)	3 POS 3 false NEG
ON1	NEG	1 (6)	6 NEG
ON2	NEG	1 (6)	6 NEG

Globally, on the 30 encoded results, 26/30 (86.7%) were correct.

Used method

Method	N	NR	NRC	%
VetMAX™ C. burnetii Absolute Quant Kit	2	10	8	80
ID.VET - ID GENE® Q FEVER TRIPLEX	1	5	5	100
VetMAX™ C. burnetii Feces Kit	1	5	5	100
RT-qPCR home made	2	10	8	80
TOTAL	6	30	26	86.7

(NR = number of results; NCR = number of correct results).

Conclusion

The participants obtained a 86.7% of success in this survey.

Milk

The panel consisted of 5 samples, but samples MP1 and MP2 were repeated twice. Therefore, 4 positive and 1 negative samples were used.

Results per sample

Sample ID	Status	Number of repetitions (total results)	Observed result
MP1	POS	2 (12)	12 POS
MP2	POS	2 (12)	12 POS
MN1	NEG	1 (6)	6 NEG

Globally, on the 30 encoded results, 30/30 (100%) were correct.

Used method

Method	N	NR	NRC	%
VetMAX™ C. burnetii Absolute Quant Kit	2	10	10	100
ID.VET - ID GENE® Q FEVER TRIPLEX	1	5	5	100
VetMAX™ C. burnetii Feces Kit	1	5	5	100
RT-qPCR home made	2	10	10	100
TOTAL	6	30	30	100

(NR = number of results; NCR = number of correct results).

Conclusion

The participants obtained a 100% of success in this survey.

ANNEXES (NOT UNDER ACCREDITATION)

The boxplots were performed using the shiny.chemgrid.org/boxplotr/ software.

Annex 1: Quantitative results

Sample: PT2021QFVBACMP1

	97504	97507	97510	97522	97523	97534
Rep 1	29.1	27.7	25.8	25.1	30.8	24.7
Rep 2	29.2	26.4	26.5	25.3	31.2	26.6
Average	29.1	27.0	26.2	25.2	31.0	25.6
SD	0.08	1.0	0.5	0.2	0.3	1.3
CV	0%	4%	2%	1%	1%	5%




Figure A1. Dispersion of the Ct values (box-plots) per laboratory.

Sample: PT2021QFVBACMP2

	97504	97507	97510	97522	97523	97534
Rep 1	31.1	28.1	27.1	27.0	32.4	26.8
Rep 2	31.1	28.4	27.9	27.2	31.1	26.6
Average	31.1	28.2	27.5	27.1	32.3	26.7
SD	0.02	0.2	0.6	0.2	0.2	0.1
CV	0%	1%	2%	1%	1%	1%




Figure A2. Dispersion of the Ct values (box-plots) per laboratory.

Annex 2: Additional information


The preliminary report of this survey is available on our website via the following link:
https://www.wiv-isp.be/QML/activities/PT%20VET/fr/originaux/rapports_annee.htm

The calendar for Proficiency Testing in Veterinary diagnosis is available on our website:
https://www.wivisp.be/QML/activities/external_quality/calendar/calender_PT%20VET/fr/Calendrier_2020-PT%20VET%202.htm

Graphical representation

Besides the tables with the results a "Box and whisker" plot is added. It contains the following elements for the methods with at least 3 participants:

- A rectangle ranging from percentile 25 (P_{25}) to percentile 75 (P_{75})
- A central line representing the median of the results (P_{50})
- A lower limit showing the smallest value $x > P_{25} - 1.5 * (P_{75} - P_{25})$
- An upper limit representing the largest value $x < P_{75} + 1.5 * (P_{75} - P_{25})$
- All points outside this interval are represented by a dot



Corresponding limits in case of normal distribution

© Sciensano, Brussels 2021.

This report may not be reproduced, published or distributed without the consent of Sciensano. The laboratories' individual results are confidential. They are not passed on by Sciensano to third parties, nor to members of the Commission, the committees of experts or the working group EQA.

END